At this year’s Transcatheter Cardiovascular Therapeutics meeting, companies presented work comparing shortened durations of dual anti-platelet therapy with the standard 1-year regimen in patients treated with a drug-eluting stent.
Among those companies were Medtronic (NYSE:MDT) and OrbusNeich. Here’s a look at what they found.
Get the full story at our sister site, Drug Delivery Business News.
The post TCT 2017: Medtronic & OrbusNeich evaluate shortening dual antiplatelet therapy with drug-eluting stents appeared first on MassDevice.
from MassDevice http://ift.tt/2A43ecd
Cap comentari:
Publica un comentari a l'entrada